US 10,208,125 B2Granted

Anti-mucin 1 binding agents and uses thereof

AssigneesUniversity of Pittsburgh—Of the Commonwealth System of Higher Education, Bluefin BioMedicine, Inc.

InventorsRobert E. Schoen, Olivera J. Finn, Shuji Sato, Wan Cheung Cheung, Roberto D. Polakiewicz

Life of this patent

Estimating the term…

Abstract

This disclosure provides anti-MUC1 binding agents (e.g., antibodies and chimeric antigen receptors) and methods of treatment, prophylaxis, detection, and diagnosis using the same.

Claims44

Dependent claims

A purified anti-MUC1 binding agent comprising:

(a) a heavy chain variable region having complementarity determining regions (CDRs) 1, 2, and 3 comprising the amino acid sequences of DYYMS (SEQ ID NO:
59), YISSSG(S/T)T(I/K)YYADSVKG (SEQ ID NO:
357), and E(R/N)(I/L)GYC(S/T)GG(S/N) C(Y/F)YYYYMDV (SEQ ID NO:
360), respectively;
and a light chain variable region having CDRs 1, 2, 3, comprising the amino acid sequences of RSSQSL(V/L)(H/R)S(D/N)G(N/Y)TYL(S/H) (SEQ ID NO:
366), (K/R)(I/V)SN(R/H)(F/L)S (SEQ ID NO:
367), and (M/L)Q(A/G)(T/S)QFP(L/I/F/V)T (SEQ ID NO:
368), respectively;
(b) a heavy chain variable region having CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs:
7, 9, and 11, respectively;
and a light chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
150, 152, and 154, respectively;
(ii) SEQ ID NOs:
159, 152, and 154, respectively;
or
(iii) SEQ ID NOs:
150, 152, and 163, respectively;
(c) a heavy chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
16, 17, and 19, respectively;
(ii) SEQ ID NOs:
16, 24, and 19, respectively;
(iii) SEQ ID NOs:
29, 24, and 19, respectively;
(iv) SEQ ID NOs:
34, 17, and 36, respectively;
(v) SEQ ID NOs:
16, 17, and 36, respectively;
or
(vi) SEQ ID NOs:
16, 43, and 36, respectively;
and
a light chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
176, 178, and 180, respectively;
(ii) SEQ ID NOs:
185, 187, and 180, respectively;
or
(iii) SEQ ID NOs:
185, 138, and 180, respectively;
(d) a heavy chain variable region having CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs:
49, 51, and 53, respectively;
and a light chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
195, 197, and 199, respectively;
(ii) SEQ ID NOs:
204, 205, and 199, respectively;
(iii) SEQ ID NOs:
195, 205, and 199, respectively;
(iv) SEQ ID NOs:
216, 217, and 199, respectively;
(v) SEQ ID NOs:
195, 205, and 221, respectively;
(vi) SEQ ID NOs:
195, 205, and 226, respectively;
(vii) SEQ ID NOs:
230, 205, and 226, respectively;
(viii) SEQ ID NOs:
236, 238, and 226, respectively;
(ix) SEQ ID NOs:
247, 205, and 226, respectively;
(x) SEQ ID NOs:
251, 205, and 226, respectively;
or
(xi) SEQ ID NOs:
257, 238, and 226, respectively;
(e) a heavy chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
59, 61, and 63, respectively;
(ii) SEQ ID NOs:
59, 67, and 63, respectively;
(iii) SEQ ID NOs:
59, 61, and 72, respectively;
(iv) SEQ ID NOs:
59, 76, and 77, respectively;
(v) SEQ ID NOs:
59, 61, and 77, respectively;
(vi) SEQ ID NOs:
59, 67, and 116, respectively;
(vii) SEQ ID NOs:
59, 61, and 120, respectively;
(viii) SEQ ID NOs:
59, 61, and 84, respectively;
(ix) SEQ ID NOs:
59, 61, and 124, respectively;
(x) SEQ ID NOs:
59, 67, and 129, respectively;
or
(xi) SEQ ID NOs:
59, 61, and 89, respectively;
and
a light chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
263, 265, and 267, respectively;
(ii) SEQ ID NOs:
310, 311, and 267, respectively;
(iii) SEQ ID NOs:
263, 265, and 316, respectively;
(iv) SEQ ID NOs:
263, 265, and 320, respectively;
(v) SEQ ID NOs:
263, 265, and 325, respectively;
(vi) SEQ ID NOs:
263, 265, and 329, respectively;
(vii) SEQ ID NOs:
335, 265, and 337, respectively;
(viii) SEQ ID NOs:
263, 265, and 342, respectively;
(ix) SEQ ID NOs:
263, 265, and 271, respectively;
or
(x) SEQ ID NOs:
263, 265, and 276, respectively;
(f) a heavy chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
94, 96, and 98, respectively;
(ii) SEQ ID NOs:
49, 51, and 103, respectively;
or
(iii) SEQ ID NOs:
49, 110, and 112, respectively;
and
a light chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
263, 265, and 267, respectively;
(ii) SEQ ID NOs:
310, 311, and 267, respectively;
(iii) SEQ ID NOs:
263, 265, and 271, respectively;
or
(iv) SEQ ID NOs:
263, 265, and 276, respectively;
(g) a heavy chain variable region having CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs:
7, 9, and 11, respectively;
and a light chain variable region having CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs:
150, 152, and 163, respectively;
(h) a heavy chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
59, 61, and 63, respectively;
(ii) SEQ ID NOs:
59, 67, and 63, respectively;
(iii) SEQ ID NOs:
59, 61, and 72, respectively;
(iv) SEQ ID NOs:
59, 76, and 77, respectively;
(v) SEQ ID NOs:
59, 61, and 77, respectively;
(vi) SEQ ID NOs:
59, 67, and 116, respectively;
(vii) SEQ ID NOs:
59, 61, and 120, respectively;
(viii) SEQ ID NOs:
59, 61, and 84, respectively;
(ix) SEQ ID NOs:
59, 61, and 124, respectively;
(x) SEQ ID NOs:
59, 67, and 129, respectively;
or
(xi) SEQ ID NOs:
59, 61, and 89, respectively;
and
a light chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
263, 265, and 267, respectively;
(ii) SEQ ID NOs:
310, 311, and 267, respectively;
(iii) SEQ ID NOs:
263, 265, and 316, respectively;
(iv) SEQ ID NOs:
263, 265, and 320, respectively;
(v) SEQ ID NOs:
263, 265, and 325, respectively;
(vi) SEQ ID NOs:
263, 265, and 329, respectively;
(vii) SEQ ID NOs:
335, 265, and 337, respectively;
or
(viii) SEQ ID NOs:
263, 265, and 342, respectively;
(i) a heavy chain variable region having CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs:
7, 9, and 11, respectively;
and a light chain variable region having
(i) CDR1 comprising an amino acid sequence selected from SEQ ID NO:
150 and SEQ ID NO:
159;
(ii) CDR2 comprising an amino acid sequence set forth in SEQ ID NO:
152;
and
(iii) CDR3 comprising an amino acid sequence selected from SEQ ID NO:
154 and SEQ ID NO:
163;
(j) a heavy chain variable region having
(i) CDR1 comprising an amino acid sequence selected from SEQ ID NOs:
16, 29, and 34;
(ii) CDR2 comprising an amino acid sequence selected from SEQ ID NOs:
17, 24, and 43;
and
(iii) CDR3 comprising an amino acid sequence selected from SEQ ID NO:
19 and SEQ ID NO:
36;
and
a light chain variable region having
(i) CDR1 comprising an amino acid sequence selected from SEQ ID NO:
176 and SEQ ID NO:
185;
(ii) CDR2 comprising an amino acid sequence selected from SEQ ID NOs:
138, 178, and 187;
and
(iii) CDR3 comprising an amino acid sequence set forth in SEQ ID NO:
180;
(k) a heavy chain variable region having CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs:
49, 51, and 53, respectively;
and a light chain variable region having
(i) CDR1 comprising an amino acid sequence selected from SEQ ID NOs:
195, 204, 216, 230, 236, 247, 251, and 257;
(ii) CDR2 comprising an amino acid sequence selected from SEQ ID NOs:
197, 205, 217, and 238;
and
(iii) CDR3 comprising an amino acid sequence selected from SEQ ID NOs:
199, 221, and 226;
(l) a heavy chain variable region having
(i) CDR1 comprising an amino acid sequence set forth in SEQ ID NO:
59;
(ii) CDR2 comprising an amino acid sequence selected from SEQ ID NOs:
61, 67, and 76;
and
(iii) CDR3 comprising an amino acid sequence selected from SEQ ID NOs:
63, 72, 77, 84, 116, 120, 124, and 129;
and
a light chain variable region having
(i) CDR1 comprising an amino acid sequence selected from SEQ ID NOs:
195, 204, 216, 230, 236, 247, 251, and 257;
(ii) CDR2 comprising an amino acid sequence selected from SEQ ID NO:
265 and SEQ ID NO:
311;
and
(iii) CDR3 comprising an amino acid sequence selected from SEQ ID NOs:
267, 271, 276, 316, 320, 325, 329, 337, and 342;
(m) a heavy chain variable region having
(i) CDR1 comprising an amino acid sequence selected from SEQ ID NO:
49 and SEQ ID NO:
94;
(ii) CDR2 comprising an amino acid sequence selected from SEQ ID NOs:
51, 96, and 110;
and
(iii) CDR3 comprising an amino acid sequence selected from SEQ ID NOs:
98, 103, and 112;
and
a light chain variable region having
(i) CDR1 comprising an amino acid sequence selected from SEQ ID NOs:
285, 292, and 299;
(ii) CDR2 comprising an amino acid sequence selected from SEQ ID NOs:
205, 287, 293, and 304;
and
(iii) CDR3 comprising an amino acid sequence set forth in SEQ ID NO:
288;
(n) a heavy chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
59, 357, and 358, respectively;
(ii) SEQ ID NOs:
59, 357, and 359, respectively;
(iii) SEQ ID NOs:
59, 357, and 360, respectively;
(iv) SEQ ID NOs:
59, 357, and 361, respectively;
or
(v) SEQ ID NOs:
59, 357, and 362, respectively;
and
a light chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
263, 265, and 363, respectively;
(ii) SEQ ID NOs:
364, 265, and 365, respectively;
or
(iii) SEQ ID NOs:
366, 367, and 368, respectively;
or
(o) a heavy chain variable region having CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs:
7, 9, and 11, respectively;
and a light chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
369, 152, and 154, respectively;
or
(ii) SEQ ID NOs:
369, 152, and 370, respectively.

284 more elements

Dependencies are inferred from the claim text.

Facts

Application: 14/904,575Filed 14 Jul 2014 · us provisional application
Priority: 15 Jul 2013
Published: US 2016/0145343 A126 May 2016
Granted: 19 Feb 2019
Term ends: Not estimatedThe source records don’t support an estimate.

Classification19 codes

C07K 16/2896
Against receptors, cell surface antigens or cell surface determinants: against molecules with a "CD"-designation, not provided for elsewhere
C07K 14/7051
Immunoglobulin superfamily: t-cell receptor -CD3 complex
C07K 14/70521
Immunoglobulin superfamily: cd28, cd152
C07K 16/30
Against receptors, cell surface antigens or cell surface determinants: from tumour cells

Family

Application61/846,257Us provisional application · filed 15 Jul 2013
Application61/976,806Us provisional application · filed 8 Apr 2014
Application61/986,511Us provisional application · filed 30 Apr 2014
US 2016/0145343 A1Pre-grant publication · published 26 May 2016
US 10,208,125 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

Abstract

This disclosure provides anti-MUC1 binding agents (e.g., antibodies and chimeric antigen receptors) and methods of treatment, prophylaxis, detection, and diagnosis using the same.

A purified anti-MUC1 binding agent comprising:

(a) a heavy chain variable region having complementarity determining regions (CDRs) 1, 2, and 3 comprising the amino acid sequences of DYYMS (SEQ ID NO:
59), YISSSG(S/T)T(I/K)YYADSVKG (SEQ ID NO:
357), and E(R/N)(I/L)GYC(S/T)GG(S/N) C(Y/F)YYYYMDV (SEQ ID NO:
360), respectively;
and a light chain variable region having CDRs 1, 2, 3, comprising the amino acid sequences of RSSQSL(V/L)(H/R)S(D/N)G(N/Y)TYL(S/H) (SEQ ID NO:
366), (K/R)(I/V)SN(R/H)(F/L)S (SEQ ID NO:
367), and (M/L)Q(A/G)(T/S)QFP(L/I/F/V)T (SEQ ID NO:
368), respectively;
(b) a heavy chain variable region having CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs:
7, 9, and 11, respectively;
and a light chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
150, 152, and 154, respectively;
(ii) SEQ ID NOs:
159, 152, and 154, respectively;
or
(iii) SEQ ID NOs:
150, 152, and 163, respectively;
(c) a heavy chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
16, 17, and 19, respectively;
(ii) SEQ ID NOs:
16, 24, and 19, respectively;
(iii) SEQ ID NOs:
29, 24, and 19, respectively;
(iv) SEQ ID NOs:
34, 17, and 36, respectively;
(v) SEQ ID NOs:
16, 17, and 36, respectively;
or
(vi) SEQ ID NOs:
16, 43, and 36, respectively;
and
a light chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
176, 178, and 180, respectively;
(ii) SEQ ID NOs:
185, 187, and 180, respectively;
or
(iii) SEQ ID NOs:
185, 138, and 180, respectively;
(d) a heavy chain variable region having CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs:
49, 51, and 53, respectively;
and a light chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
195, 197, and 199, respectively;
(ii) SEQ ID NOs:
204, 205, and 199, respectively;
(iii) SEQ ID NOs:
195, 205, and 199, respectively;
(iv) SEQ ID NOs:
216, 217, and 199, respectively;
(v) SEQ ID NOs:
195, 205, and 221, respectively;
(vi) SEQ ID NOs:
195, 205, and 226, respectively;
(vii) SEQ ID NOs:
230, 205, and 226, respectively;
(viii) SEQ ID NOs:
236, 238, and 226, respectively;
(ix) SEQ ID NOs:
247, 205, and 226, respectively;
(x) SEQ ID NOs:
251, 205, and 226, respectively;
or
(xi) SEQ ID NOs:
257, 238, and 226, respectively;
(e) a heavy chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
59, 61, and 63, respectively;
(ii) SEQ ID NOs:
59, 67, and 63, respectively;
(iii) SEQ ID NOs:
59, 61, and 72, respectively;
(iv) SEQ ID NOs:
59, 76, and 77, respectively;
(v) SEQ ID NOs:
59, 61, and 77, respectively;
(vi) SEQ ID NOs:
59, 67, and 116, respectively;
(vii) SEQ ID NOs:
59, 61, and 120, respectively;
(viii) SEQ ID NOs:
59, 61, and 84, respectively;
(ix) SEQ ID NOs:
59, 61, and 124, respectively;
(x) SEQ ID NOs:
59, 67, and 129, respectively;
or
(xi) SEQ ID NOs:
59, 61, and 89, respectively;
and
a light chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
263, 265, and 267, respectively;
(ii) SEQ ID NOs:
310, 311, and 267, respectively;
(iii) SEQ ID NOs:
263, 265, and 316, respectively;
(iv) SEQ ID NOs:
263, 265, and 320, respectively;
(v) SEQ ID NOs:
263, 265, and 325, respectively;
(vi) SEQ ID NOs:
263, 265, and 329, respectively;
(vii) SEQ ID NOs:
335, 265, and 337, respectively;
(viii) SEQ ID NOs:
263, 265, and 342, respectively;
(ix) SEQ ID NOs:
263, 265, and 271, respectively;
or
(x) SEQ ID NOs:
263, 265, and 276, respectively;
(f) a heavy chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
94, 96, and 98, respectively;
(ii) SEQ ID NOs:
49, 51, and 103, respectively;
or
(iii) SEQ ID NOs:
49, 110, and 112, respectively;
and
a light chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
263, 265, and 267, respectively;
(ii) SEQ ID NOs:
310, 311, and 267, respectively;
(iii) SEQ ID NOs:
263, 265, and 271, respectively;
or
(iv) SEQ ID NOs:
263, 265, and 276, respectively;
(g) a heavy chain variable region having CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs:
7, 9, and 11, respectively;
and a light chain variable region having CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs:
150, 152, and 163, respectively;
(h) a heavy chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
59, 61, and 63, respectively;
(ii) SEQ ID NOs:
59, 67, and 63, respectively;
(iii) SEQ ID NOs:
59, 61, and 72, respectively;
(iv) SEQ ID NOs:
59, 76, and 77, respectively;
(v) SEQ ID NOs:
59, 61, and 77, respectively;
(vi) SEQ ID NOs:
59, 67, and 116, respectively;
(vii) SEQ ID NOs:
59, 61, and 120, respectively;
(viii) SEQ ID NOs:
59, 61, and 84, respectively;
(ix) SEQ ID NOs:
59, 61, and 124, respectively;
(x) SEQ ID NOs:
59, 67, and 129, respectively;
or
(xi) SEQ ID NOs:
59, 61, and 89, respectively;
and
a light chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
263, 265, and 267, respectively;
(ii) SEQ ID NOs:
310, 311, and 267, respectively;
(iii) SEQ ID NOs:
263, 265, and 316, respectively;
(iv) SEQ ID NOs:
263, 265, and 320, respectively;
(v) SEQ ID NOs:
263, 265, and 325, respectively;
(vi) SEQ ID NOs:
263, 265, and 329, respectively;
(vii) SEQ ID NOs:
335, 265, and 337, respectively;
or
(viii) SEQ ID NOs:
263, 265, and 342, respectively;
(i) a heavy chain variable region having CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs:
7, 9, and 11, respectively;
and a light chain variable region having
(i) CDR1 comprising an amino acid sequence selected from SEQ ID NO:
150 and SEQ ID NO:
159;
(ii) CDR2 comprising an amino acid sequence set forth in SEQ ID NO:
152;
and
(iii) CDR3 comprising an amino acid sequence selected from SEQ ID NO:
154 and SEQ ID NO:
163;
(j) a heavy chain variable region having
(i) CDR1 comprising an amino acid sequence selected from SEQ ID NOs:
16, 29, and 34;
(ii) CDR2 comprising an amino acid sequence selected from SEQ ID NOs:
17, 24, and 43;
and
(iii) CDR3 comprising an amino acid sequence selected from SEQ ID NO:
19 and SEQ ID NO:
36;
and
a light chain variable region having
(i) CDR1 comprising an amino acid sequence selected from SEQ ID NO:
176 and SEQ ID NO:
185;
(ii) CDR2 comprising an amino acid sequence selected from SEQ ID NOs:
138, 178, and 187;
and
(iii) CDR3 comprising an amino acid sequence set forth in SEQ ID NO:
180;
(k) a heavy chain variable region having CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs:
49, 51, and 53, respectively;
and a light chain variable region having
(i) CDR1 comprising an amino acid sequence selected from SEQ ID NOs:
195, 204, 216, 230, 236, 247, 251, and 257;
(ii) CDR2 comprising an amino acid sequence selected from SEQ ID NOs:
197, 205, 217, and 238;
and
(iii) CDR3 comprising an amino acid sequence selected from SEQ ID NOs:
199, 221, and 226;
(l) a heavy chain variable region having
(i) CDR1 comprising an amino acid sequence set forth in SEQ ID NO:
59;
(ii) CDR2 comprising an amino acid sequence selected from SEQ ID NOs:
61, 67, and 76;
and
(iii) CDR3 comprising an amino acid sequence selected from SEQ ID NOs:
63, 72, 77, 84, 116, 120, 124, and 129;
and
a light chain variable region having
(i) CDR1 comprising an amino acid sequence selected from SEQ ID NOs:
195, 204, 216, 230, 236, 247, 251, and 257;
(ii) CDR2 comprising an amino acid sequence selected from SEQ ID NO:
265 and SEQ ID NO:
311;
and
(iii) CDR3 comprising an amino acid sequence selected from SEQ ID NOs:
267, 271, 276, 316, 320, 325, 329, 337, and 342;
(m) a heavy chain variable region having
(i) CDR1 comprising an amino acid sequence selected from SEQ ID NO:
49 and SEQ ID NO:
94;
(ii) CDR2 comprising an amino acid sequence selected from SEQ ID NOs:
51, 96, and 110;
and
(iii) CDR3 comprising an amino acid sequence selected from SEQ ID NOs:
98, 103, and 112;
and
a light chain variable region having
(i) CDR1 comprising an amino acid sequence selected from SEQ ID NOs:
285, 292, and 299;
(ii) CDR2 comprising an amino acid sequence selected from SEQ ID NOs:
205, 287, 293, and 304;
and
(iii) CDR3 comprising an amino acid sequence set forth in SEQ ID NO:
288;
(n) a heavy chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
59, 357, and 358, respectively;
(ii) SEQ ID NOs:
59, 357, and 359, respectively;
(iii) SEQ ID NOs:
59, 357, and 360, respectively;
(iv) SEQ ID NOs:
59, 357, and 361, respectively;
or
(v) SEQ ID NOs:
59, 357, and 362, respectively;
and
a light chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
263, 265, and 363, respectively;
(ii) SEQ ID NOs:
364, 265, and 365, respectively;
or
(iii) SEQ ID NOs:
366, 367, and 368, respectively;
or
(o) a heavy chain variable region having CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs:
7, 9, and 11, respectively;
and a light chain variable region having CDRs 1, 2, and 3 comprising a set of amino acid sequences set forth in
(i) SEQ ID NOs:
369, 152, and 154, respectively;
or
(ii) SEQ ID NOs:
369, 152, and 370, respectively.

284 more elements

Facts

Application

14/904,575Filed 14 Jul 2014 · us provisional application

Priority

15 Jul 2013

Published

US 2016/0145343 A126 May 2016

Granted

19 Feb 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification19 codes

C07K 16/2896
Against receptors, cell surface antigens or cell surface determinants: against molecules with a "CD"-designation, not provided for elsewhere
C07K 14/7051
Immunoglobulin superfamily: t-cell receptor -CD3 complex
C07K 14/70521
Immunoglobulin superfamily: cd28, cd152
C07K 16/30
Against receptors, cell surface antigens or cell surface determinants: from tumour cells

Family

Application61/846,257Us provisional application · filed 15 Jul 2013

Application61/976,806Us provisional application · filed 8 Apr 2014

Application61/986,511Us provisional application · filed 30 Apr 2014

US 2016/0145343 A1Pre-grant publication · published 26 May 2016

US 10,208,125 B2This patent

From the US filing history. Foreign family members aren’t listed.